Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Three Cannabis Stocks You Cannot Afford To Miss

May 7, 2015 • 6:00 PM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The emergence of the cannabis industry has created a number of wealth building opportunities for investors. There are more 250 publicly traded cannabis companies, however, most of them will dissolve or shut down over the next two years. Today, we are going to discuss 5 companies that every investor should have on their radar.

GW Pharmaceuticals plc (GWPH: NASDAQ)

GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. The company commercialized the first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex, which is in Phase 3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. The company has a deep pipeline of cannabinoid product candidates which should lead to exponential revenue growth for years to come.

Recent developments

  • May 6, 2015: GWPH commenced a Phase 2 clinical trial of GWP42006 in adult patients with epilepsy. GWP42006 is the non-psychoactive cannabinoid cannabidivarin (CBDV) extracted from the cannabis plant.

  • May 5, 2015: GWPH closes a U.S. public offering and raised approximately $179.2 Million.

  • April 27, 2015: The United States Patent and Trademark Office issued GWPH a notice of allowance for a patent application which covers the use of cannabidivarin (CBDV) for treating epilepsy.

  • April 23, 2015: Bank of America/Merrill Lynch raise GWPH’s price target to $155 from $115.

Insys Therapeutics, Inc. (INSY: NASDAQ)

Insys Therapeutics, Inc. is commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. INSY is one of the few NASDAQ traded companies that is focused on the development of medicines derived from the cannabis plant. We have a favorable view on the future outlook of INSY for the following reasons: 1) the FDA has granted them the orphan drug designation (ODD) on a variety of treatments in their extensive product pipeline, 2) they have favorable street coverage that offers significant upside potential, 3) their two marketed products can lead to exponential revenue growth, and 4) first quarter financial results showed significant improvement.

Recent Developments

  • May 7, 2015: INSY announced first quarter financial results. The company generated over $70 million in revenue (91% gross margins) and $8.0 million in net income.

  • May 7, 2015: The board of directors approved a 2-for-1 stock split. The ex-dividend date is is May 21, 2015. This means if an investor wants to be entitled to the stock dividend they must own INSY as of May 20, 2015.

  • April 23, 2015: The company started dosing pediatric epilepsy patients in a Phase 1/2 safety and pharmacokinetic study in pediatric subjects with treatment-resistant seizures.

  • March 3, 2015: INSY beats Wall Street estimates for fourth quarter revenue.

Mentor Capital, Inc. (MNTR: OTCQB)

Mentor Capital, Inc. is a private equity firm specializing in acquisitions. The firm provides passive equity funding and liquidity to smaller companies in the cannabis industry. MNTR invests in shelf IPO’s and public and private companies and seeks to provide public market access to owners of small private companies.

Recent Developments

  • April 22, 2015: Acquired Cannabis Investor Webcast

  • April 14, 2015: Arranged for $1.3 million in long term financing

  • April 10, 2015: Hired an executive to focus on spinning off subsidiaries

  • March 31, 2015: Reported 2.1 million in revenue during 2014

  • March 30, 2015: Accepted for DTC FAST Program for DWAC and DRS Handling Business

  • February 9, 2015: Uplisted onto the OTCQB exchange

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.